InsidersTradesSigma
Intervacc AB Stock: price and directors' dealings · Finland · FIN-FSA
Track the Intervacc AB stock price and the full insider trade history of the company, a listed equity based in Finland. Shares are listed on FI FI, under the authority of FIN-FSA. Operating in the Health Care sector, Intervacc AB has recorded 20 reports. Market capitalisation: €446.5m. The latest transaction was disclosed on 9 July 2026 (Purchase). Among the most active insiders: Carl Johan Dalsgaard. All data is free.
20
Insider Decl.
0
Thresholds
€4m
20 ops.
Buy Volume
·
0 ops.
Sell Volume
45Σ signal
Fundamental score
Ranked 25,533 of 25,927 companies
8.4
score / 100
Value12
Quality5
FCF yld-15%
Earn yld-18%
EV/EBITDA·
ROE-30%
Gross mgn-57%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 July 2026
Declarations20 total
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
25,000 shares@ SEK 1.290.0072% mcap13.1% of flowAktieFI:csv-cfe59bf3ca5bb69e9a3c
Ideal exit: 4 Apr 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
47,442 shares@ SEK 1.2860.0012% mcap50.5% of flowAktieFI:csv-f35e886c723748d43bbb
Ideal exit: 22 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
2,558 shares@ SEK 1.2860.0001% mcap2.7% of flowAktieFI:csv-d616550790a3f71f2f72
Ideal exit: 23 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
5,751 shares@ SEK 1.2520.0001% mcap5.9% of flowAktieFI:csv-9ef6683544067d278309
Ideal exit: 23 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
50,000 shares@ SEK 1.300.0013% mcap30.6% of flowAktieFI:csv-20c1d0a5f0a1d2206d77
Ideal exit: 15 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
38,000 shares@ SEK 1.290.0010% mcap100.0% of flowAktieFI:csv-7a163a2b3ec081104e0a
Ideal exit: 15 Mar 2027 (T+270)
25,407 shares@ SEK 1.33550.0007% mcap10.0% of flowAktieFI:csv-0272bf8ff21dbecadbb7
Ideal exit: 12 Mar 2027 (T+270)
224,593 shares@ SEK 1.36270.0061% mcap90.0% of flowAktieFI:csv-a553766ecf58ec5fb2e8
Ideal exit: 9 Mar 2027 (T+270)
192,413 shares@ SEK 1.29510.0052% mcap28.2% of flowAktieFI:csv-7952072405c3c0a516d7
Ideal exit: 8 Mar 2027 (T+270)
7,587 shares@ SEK 1.260.0002% mcap1.5% of flowAktieFI:csv-e708bf289dd7f51b22c3
Ideal exit: 6 Mar 2027 (T+270)
200,000 shares@ SEK 1.29790.0055% mcap41.4% of flowAktieFI:csv-a74d4efb00d408c9d32a
Ideal exit: 5 Mar 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
20,347 shares@ SEK 1.190.0005% mcap16.6% of flowAktieFI:csv-521171914fa637001fb5
Ideal exit: 28 Feb 2027 (T+270)
●
Annan medlem i bolagets administrations-, lednings- eller kontrollorganExecutives
20,347 shares@ SEK 1.190.0005% mcap19.9% of flowAktieFI:A003Z612-1
Ideal exit: 28 Feb 2027 (T+270)
150,000 shares@ SEK 1.150.44% mcap49.8% of flowAktieFI:csv-a7914a02e2b1146dec19
Ideal exit: 13 Feb 2027 (T+270)
150,000 shares@ €12.54360.46% mcap99.2% of flowAktieFI:A003Y813-1
Ideal exit: 13 Feb 2027 (T+270)
200,000 shares@ €0.0580.0028% mcap35.4% of flowAktieFI:A003W618-1
Ideal exit: 24 Nov 2026 (T+270)
130,000 shares@ €0.06860.0022% mcap100.0% of flowAktieFI:A003W620-1
Ideal exit: 15 Nov 2026 (T+270)
100,000 shares@ €0.07020.0017% mcap21.5% of flowAktieFI:A003W345-1
Ideal exit: 17 Nov 2026 (T+270)
200,000 shares@ €0.07050.0035% mcap43.1% of flowAktieFI:A003W152-1
Ideal exit: 15 Nov 2026 (T+270)
180,000 shares@ €0.08840.0039% mcap100.0% of flowAktieFI:A003Q915-1
Ideal exit: 17 Apr 2026 (T+270)
20 of 20 declarations
About Intervacc AB
Intervacc AB is a Swedish company focused on the development of vaccines for animals. It aims to provide innovative solutions to enhance animal health.